Aditxt

Aditxt Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Aditxt (ADTX) as of Nov 21, 2026 is 61,581.81 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 48.66 % — a change of 126,450.03% (higher).

Cash Conversion

61,581.81 %

YoY

126,450.03%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Aditxt is 2025 61,581.81 % . Cash Conversion Rate (OCF/Net Income) of Aditxt was 2024 48.66 % . It decreases by 126,450.03% higher compared to the previous year.

The Aditxt Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
6.79 USD
Jan 1, 2019
7.97 USD
Jan 1, 2020
78.92 USD
Jan 1, 2021
48.04 USD
Jan 1, 2022
80.98 USD
Jan 1, 2023
57.37 USD
Jan 1, 2024
48.66 USD
Jan 1, 2025
61,581.81 USD
The Aditxt Cash Conversion history
YEARCash ConversionYoY
61,581.81 %+126,450.03%
48.66 %-15.18%
57.37 %-29.16%
80.98 %+68.56%
48.04 %-39.13%
78.92 %+890.85%
7.97 %+17.32%
6.79 %-96.26%
181.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aditxt Stock analysis

What does Aditxt do? ADiTx Therapeutics, Inc. develops nucleic acid-based technologies for organ transplant tolerance and immune system health. The company's Apoptotic DNA Immunotherapy (ADi) reprograms the immune system to induce tolerance, while Aditxt Immune Monitor (AiM) provides personalized immune profiles. Both technologies are in preclinical development, with the firm focusing on minimizing transplant rejection and addressing autoimmune diseases and allergies. The company is headquartered in Mountain View, California and employs 2 full-time staff. ADiTx Therapeutics, Inc. generates revenue through the development and potential future commercialization of its immune reprogramming and monitoring technologies. The company is a preclinical stage life sciences entity targeting medical applications in organ transplantation and immune-related conditions. Its core products, ADi and AiM, are designed to address unmet medical needs in immune system management. The firm's focus on immune reprogramming and monitoring positions it for potential partnerships with healthcare providers and biopharmaceutical companies in the future. Aditxt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aditxt stock

Cash Conversion Rate (OCF/Net Income) of Aditxt is 61,581.81 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Aditxt changed from 48.66 % to 61,581.81 %, representing a 126,450.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Aditxt since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Aditxt with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Aditxt

All Key Metrics — Aditxt